Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary AdenocarcinomaJohn P. Neoptolemos, Alan Anthoney, Paula Ghaneh et al.|JAMA|2012Cited by 590
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, Paul Silcocks et al.|The Lancet Oncology|2014Cited by 374
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 TrialWilliam Greenhalf, Markus W. Büchler, Paula Ghaneh et al.|JNCI Journal of the National Cancer Institute|2013Cited by 333
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, John P. Neoptolemos, Daniel H. Palmer et al.|The Lancet Oncology|2017Cited by 73
Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.John P. Neoptolemos, Malcolm J. Moore, Trevor F. Cox et al.|Journal of Clinical Oncology|2011Cited by 24